Technology is constantly utilised to drive the transformation of healthcare, making it a promising sector for long-term investment.
These 7 AIM-listed companies are designers, manufacturers and producers of this evolution, bringing to the market a high quality range of innovative medical research, devices and supplies.
is a leading developer and marketer of neuroscience technologies, optimising the assessment of brain health utilising scientifically validated digital health solutions.
The Company uses its healthcare technology to measure cognitive health, from memory impairment to mental wellbeing, using a number of applications to enable clinicians to maximise the effect of treatments, improve wellbeing and save costs.
is a developer of AI products enabling clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally.
The Company works in the development of AI applications utilising patient data, blood-based biomarkers and genomics to target the chronic kidney disease (CKD) market. The company expects to launch its clinical-based solution KidneyIntelXTM later this year.
specialises in research, development and the production of kits to aid the diagnosis of autoimmune and infectious diseases as one of the UK’s leading companies in the fast growing area of immunoassay.
The company’s high quality IVD products are used in hospitals, blood banks, clinics and laboratories in over 75 countries. VISITECT® CD4 is a groundbreaking point-of-care test for CD4 in people living with HIV - it is based on proven lateral flow technology and provides an affordable, convenient, instrument-free solution for use in laboratories and remote clinics worldwide.
are an innovative R&D company with a pipeline of products working towards commercialisation, focusing on transdermal delivery to target sexual health and pain.
Futura’s highly efficient and proprietary drug delivery technology platform, DermaSys® is designed to drive more active compound through the skin, enabling a targeted and rapid delivery of active pharmaceutical ingredients (“API”) through the skin to the required site of action.
specialise in the design, development and manufacture of creative solutions to genuine clinical needs in the operating theatre environment.
Theses reliable solutions take form in product innovations for minimally invasive surgery, designing cost-effective laparoscopic instruments from retraction to port access, ensuring high quality manufacturing and environmental benefits.
is a digital healthcare company developing clinically validated software applications combining Artificial intelligence and ethically sourced, anonymised patient data.
The company hosts a range of innovative products such as EDGE, a prescribed digital therapeutic developed by the University of Oxford, monitoring chronic obstructive pulmonary disease (COPD) at home. CleanSpace allows long-term monitoring of air pollution to identify hotspots where data can be used to research links between pollution and chronic disease.
is a global supplier of medical technology for critical care, operating theatre and home healthcare applications. The company provides innovative products to both patients and caregivers, optimising patient outcomes and efficiencies of healthcare organisations.
In March, the company received the largest order for a patient warming system, shipped to over 200 hospitals for treating newborn babies throughout Poland. The system, AlphaCore5, is designed for use in operating theatres, delivery suites, and neonatal intensive care units.
Alongside this, the company’s wider product portfolio touches many other areas including; Neonatal Care, Paediatric Intensive Care, Intensive Care, Anaesthesia, Infusion Therapy, Perfusion and Vacuum Regulation.
Learn more about Artificial Intelligence in Medical Technologies here.
The author is not a registered investment adviser, nor authorized or regulated by the Financial Conduct Authority and does not provide investment advice or recommendations. Prices of the investments referred to in the article (if any) are indicative only and may go down as well as up and investors may realise losses on them. This article should not be read as an offer or recommendation to buy or sell or a solicitation of an offer or recommendation to buy or sell any securities. Although based on information believed to be accurate and complete, the content of this article is not guaranteed to be accurate or current and the reader should conduct independent verification. No liability is accepted for any loss or damage incurred from acting or not acting on this article which is educational only and does not constitute legal, investment or financial advice.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Xpediator discuss the highs and lows from 2019 and what's to come in 2020. Cora Gold discuss their maiden resource at Sanankoro and also provides an update on Hummingbird Resources. Russ Mould talks about the Saudi Aramco IPO & OPEC's latest meeting.
“We are delighted to welcome Ged Hall to the Board at such an exciting time as we look to progress the Mahenge Liandu graphite project from exploration to production,” said Johansen.
ReNeuron said it was in ongoing discussions with other commercial third parties for potential out-licence deals and Chief Executive, Olav Hellebø, says he expects to announce further deals “in the months ahead.”
Lawrence Stroll, the billionaire owner of the Racing Point Formula One motor racing team, is said to be preparing to bid for a significant stake in Aston Martin, BP has increased its stake in the British solar venture Lightsource BP as it prepares to strike a deal to power its offices with renewable energy from next year
O2 announced the launch of O2 extras this morning to offer flexibility and affordability for its customers -- the programme will be on offer to new and upgrading pay monthly customers on a handset, tablet or SIM only contracts.
Nuformix (NFX) Chief Executive Officer Dr. Dan Gooding discusses some of the speculation surrounding the leaked article in the press, answers questions investors had regarding upcoming licensing deals, and discusses a potential exit strategy for the company.